merek dagang untuk preparat doksorubisin hidroklorida.
|Trade names||Adriamycin, Doxil, Caelyx, Myocet, others|
|Bioavailability||5% (by mouth)|
|Biological half-life||Triphasic; 12 minutes, 3.3 hours, 30 hours. Mean: 1-3 hours|
|Excretion||Urine (5-12%), faeces (40-50%)|
|Chemical and physical data|
|Molar mass||543.52 g/mol|
|3D model (Jmol)|
|(what is this?)|
Doxorubicin, sold under the trade names Adriamycin among others, is a chemotherapy medication used to treat cancer. This includes breast cancer, bladder cancer, Kaposi's sarcoma, lymphoma, and acute lymphocytic leukemia. It is often used together with other chemotherapy agents. Doxorubicin is given by injection into a vein.
Common side effects include hair loss, bone marrow suppression, vomiting, rash, and inflammation of the mouth. Other serious side effects may include allergic reactions such as anaphylaxis, heart damage, tissue damage at the site of injection, radiation recall, and treatment-related leukemia. People often experience red discoloration of the urine for a few days. Doxorubicin is in the anthracycline and antitumor antibiotic family of medications. Its works in part by interfering with the function of DNA.
Doxorubicin was approved for medical use in the United States in 1974. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. The wholesale cost in the developing world is about 3.88 to 32.79 USD per 50 mg vial. In the United Kingdom this amount costs the NHS about £100.12. Versions that are pegylated and in liposomes are also available; however, are more expensive. Doxorubicin was originally made from the bacteria Streptomyces peucetius.